Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1151-1160 of 1761 for

Edit search filters
  1. A Study Of CGM In GBM

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

    Rochester, MN

  3. Tazemetostat In Combination With Doxorubicin As Frontline Therapy For Advanced Epithelioid Sarcoma

    Jacksonville, FL

  4. Combination Chemotherapy With Or Without Blinatumomab In Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

    Rochester, MN

  5. Long-Term Study Of Participants Previously With Ciltacabtagene Autoleucel

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. Study Of Lenzilumab And Axicabtagene Ciloleucel In Subjects With Relapsed Or Refractory Large B-cell Lymphoma

    Rochester, MN

  8. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  9. Expanded Access Program With Nivolumab (BMS-936558) In Combination With Ipilimumab (Yervoy®) In Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable Or Metastatic Melanoma (CheckMate 218)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Nivolumab In Treating Patients With Relapsed Or Refractory Peripheral T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer